Amsterdam: The European Medicines Agency’s human medicines committee recommended six new medicines for approval at its CHMP October 2026 meeting, held from 12 to 15 October. The list covers an oral weight-loss and diabetes drug, a pancreatic cancer treatment, two biosimilars and treatments for glioblastoma and a childhood bone disorder, according to a trade report of the session.

The headline product is Foundayo, the brand name given to orforglipron. It is an oral GLP-1 receptor agonist taken as a once-daily tablet, recommended for weight management and type 2 diabetes in adults. The report gives no dose, trial data or applicant name, so the scale of the opinion is clear only in outline. A European Commission decision normally follows within about 67 days of a CHMP opinion, which would place any authorisation in the first quarter of 2027.

Oncology supplies two more CHMP October 2026 opinions. Rasonque, containing daraxonrasib, is recommended for metastatic pancreatic adenocarcinoma and was reviewed under the agency’s Cancer Medicines Pathfinder project. Kizfizo, a temozolomide product submitted through a hybrid application, is recommended for glioblastoma multiforme in adults and malignant glioma in children.

The committee also backed two biosimilars. Fovlussea, a ranibizumab biosimilar, is meant for retinal conditions, while Neuzafy, a filgrastim biosimilar, targets neutropenia. Yuviwel, containing navepegritide, received a positive opinion for achondroplasia in children. For parents of children with that condition, a recommendation from the CHMP October 2026 session marks a step toward an approved therapy in the EU.

The CHMP October 2026 meeting produced five extensions of indication. The report names Kyinsu, Talvey, Tryngolza, Tukysa and AstraZeneca’s H5N1 pandemic influenza vaccine, though it gives no detail on the new uses. It also records a negative opinion for Yartemlea, containing narsoplimab, for thrombotic microangiopathy linked to haematopoietic stem cell transplantation. The committee confirmed that opinion after a re-examination, which closes the regulatory route for that indication in the EU unless the applicant returns with new evidence.

Readers should treat the details with care. The account comes from a secondary trade report, not from the agency’s own meeting highlights, and it leaves out applicant names, reference products and whether any opinion was conditional or accelerated. Two withdrawals mentioned in the report also look inconsistent with the products’ usual labelling, so they are left out here until the agency’s page confirms them.

The practical message from the CHMP October 2026 session for health systems is straightforward. Oral incretin therapy could widen access to obesity treatment, biosimilars can lower costs for hospitals, and each positive opinion starts a countdown to a binding Commission decision. The agency’s own highlights page remains the reference for the final wording of every CHMP October 2026 opinion.